The Labour manifesto pledged to “maximise our potential to lead the world in clinical trials”. With our regulatory advantage ...

In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...

OncoZenge AB (publ) (“OncoZenge” or the “Company”) announces that the Company has entered into a binding agreement to partner with L. Molteni & C. dei F.lli Alitti, Società di Esercizio S.p.A ...

Santhera Pharmaceuticals (SIX: SANN) announces that at its Capital Markets Day (CMD) in Zurich today, the Company will discuss the commercial progress with the global roll-out of AGAMREE® for the ...

Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under which Paratek will acquire Optinose, including its approved product ...

Jeddah – United Pharmacies Group has announced the signing of its first strategic agreement for the manufacturing of private-label pharmaceutical and therapeutic products in partnership with Avalon ...

For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined ...

Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

The growing burden of misinformation is a complex issue that demands a direct-to-patient channel through trusted sources. By ...

Through our deep relationships in the pediatric endocrinology community, we've come to appreciate the significant need ... pharmaceutical company focused on developing and commercializing treatments ...